Purpose of Review: The immune-mediated neuropathies are an important group of treatable neuropathies that often lead to severe neurologic disability. This review guides clinicians in the recognition and treatment of these disorders.
Recent Findings: Advances include new insights in classification and new treatment paradigms in many of these disorders.
Summary: Proper diagnosis and treatment require recognition of the characteristic clinical and laboratory findings and the use of appropriate electrophysiologic or pathologic examination. With proper treatment, partial or complete remission is possible, even in patients who are severely affected.
Address correspondence to Dr Yuen T. So, Stanford University Department of Neurology, 300 Pasteur Drive, Room A342, Stanford, CA 94305, email@example.com.
Relationship Disclosure: Dr So serves on the advisory board of Elan Pharmaceuticals, Inc. and has performed various litigation consultations.
Unlabeled Use of Products/Investigational Use Disclosure: Dr So reports no disclosure.